A federal appeals court delivered a major victory Friday for women, unborn children, and states seeking to enforce pro-life protections by temporarily blocking the mailing of the abortion drug mifepristone into Louisiana.
The United States Court of Appeals for the Fifth Circuit granted Louisiana’s request to pause the U.S. Food and Drug Administration’s 2023 decisions that allowed mifepristone to be dispensed by mail without an in-person visit to a medical provider, despite Louisiana’s abortion restrictions. The ruling temporarily halts both telemedicine prescribing and mail distribution of mifepristone nationwide while the appeal continues.
The case, Louisiana v. FDA, challenges what pro-life advocates have described as dangerous deregulation of chemical abortion drugs and the removal of critical safeguards for women.
Louisiana argued that allowing abortion pills to be prescribed through telemedicine and mailed directly to patients made it difficult to enforce the state’s near-total abortion ban and enabled the drug to enter the state despite pro-life protections already in place.
In its order, the Fifth Circuit agreed that “Louisiana has shown that it is irreparably harmed without a stay,” citing concerns that abortion drugs were being shipped into the state despite its laws.
A federal district court in Louisiana had previously declined to pause the mail-order policy in April, instead delaying proceedings while the FDA conducts an ongoing safety review of mifepristone expected to continue through later this year.
Pro-life leaders responded swiftly to the news:
Jor-El Godsey, president of Heartbeat International, called the decision “a win for women and for common-sense medical care.”
“Women deserve better than dangerous abortion drugs sent through the mail without physician oversight or in-person support,” Godsey said. “This is one step closer to ensuring women have access to real healthcare, real compassion, and life-affirming options—not isolation and risk disguised as convenience.”
Alliance Defending Freedom, which is representing Louisiana, also celebrated the ruling.
“Victory — shipment of mail-order abortion drugs is paused,” the organization posted, noting that the Fifth Circuit granted its motion to stay and that shipments are now paused nationwide while the appeal proceeds.
Louisiana Attorney General Liz Murrill also celebrated the ruling, writing,
“Victory for Life! U.S. Fifth Circuit blocks Biden abortion regime that facilitated the death of thousands of Louisiana babies through mail-order abortion pills.”
Murrill credited her office and Alliance Defending Freedom for the legal victory and pledged to continue defending women and children as the case moves forward.
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, called the decision “a huge victory for victims and survivors of Biden’s reckless mail-order abortion drug regime.”
She pointed to the growing concerns surrounding abortion drug coercion, complications from unsupervised chemical abortions, and what she described as the FDA’s unscientific removal of safeguards such as in-person physician visits.
American Association of Pro-Life Obstetricians and Gynecologists described the ruling as “a victory for both of our patients: women and their preborn children,” adding that the group would continue advocating for evidence-based care that protects women.
Lila Rose called the ruling a “big win,” urging the Trump administration to take further action and remove the abortion pill from the market entirely. "This will pause the reckless push to flood the nation with the drug used in the majority of abortions, ending the lives of preborn children and putting women at risk. Trump admin must pull the abortion pill!"
Kristan Hawkins of Students for Life notes this is a step in the right direction. "PRAISE GOD! The battle is not won yet, but this is a huge victory in the fight to end chemical abortion. Lives will be saved every day this remains in effect!"
Chemical abortion now accounts for the majority of abortions in the United States, with mifepristone often shipped directly to women’s homes after online consultations or without in-person medical oversight. Pregnancy help leaders and pro-life medical professionals have increasingly raised concerns about the physical risks, emotional trauma, and lack of follow-up care associated with mail-order abortion drugs.
Friday’s ruling signals renewed judicial scrutiny of the FDA’s abortion pill policies and could set the stage for the issue to return to the Supreme Court of the United States in the months ahead.
For pregnancy help organizations across the country, the decision represents more than a legal development—it is a reminder that women deserve real support, real healthcare, and the opportunity to choose life.
Editor's note: Heartbeat International manages Pregnancy Help News.
